This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cairns, J. A. Articles by Roberts, R. Search for Related Content PubMed PubMed Citation Articles by Cairns, J. A. Articles by Roberts, R.

Circulation, Vol 84, 550-557, Copyright © 1991 by American Heart Association

ARTICLES

Post-myocardial infarction mortality in patients with ventricular premature depolarizations. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Pilot Study

JA Cairns, SJ Connolly, M Gent and R Roberts
Department of Medicine, McMaster University, Hamilton, Ontario, Canada.

BACKGROUND. Among survivors of acute myocardial infarction, frequent and repetitive ventricular premature depolarizations (VPDs) detected on ambulatory monitoring contribute independently to the risk of all-cause mortality and sudden death. Apart from the beta-blockers, no antiarrhythmic drug has been reliably demonstrated to reduce mortality among patients with VPDs. A pilot study was undertaken to gather data to aid in the design of a multicenter trial of amiodarone for the reduction of mortality from cardiac arrhythmias in such patients. METHODS AND RESULTS. Seventy-seven patients with acute myocardial infarction within the previous 6-30 days and 10 or more VPDs/hr or one or more runs of ventricular tachycardia on 24-hour electrocardiographic recording were randomized in a double-blind fashion in a 2:1 amiodarone- to-placebo ratio. The loading dose was 10 mg/kg/day for 3 weeks. The maintenance dose was 300-400 mg/day with reductions at 4-month intervals in response to VPD suppression, excessive plasma levels, or toxicity. VPD suppression at 1 week and 2 weeks was 63% and 85%, respectively, on amiodarone and 17% and 27%, respectively, on placebo. Apart from thyroid-stimulating hormone elevation and skin reactions, no side effects occurred more frequently with amiodarone. The study drug was stopped for side effects or noncompliance in 35% of amiodarone patients and 34% of placebo patients. Patients were followed for a maximum of 2 years (mean, 20 months). Arrhythmic death or resuscitated ventricular fibrillation occurred in two of 48 amiodarone patients (6%) and four of 29 placebo patients (14%), whereas the rates of all-cause mortality were five of 48 (10%) and six of 29 (21%), respectively. CONCLUSIONS. Amiodarone, in moderate loading and maintenance dosages with adjustments in response to plasma levels, VPD suppression, and side effects, results in effective VPD suppression and acceptable levels of toxicity.

This article has been cited by other articles:

				J. W. Schrickel, J. O. Schwab, A. Yang, H. Bielik, A. Bitzen, B. Luderitz, and T. Lewalter Pro-arrhythmic effects of amiodarone and concomitant rate-control medication Europace, June 1, 2006; 8(6): 403 - 407. [Abstract] [Full Text] [PDF]

				The International Liaison Committee on Resuscitati The International Liaison Committee on Resuscitation (ILCOR) Consensus on Science With Treatment Recommendations for Pediatric and Neonatal Patients: Pediatric Basic and Advanced Life Support Pediatrics, May 1, 2006; 117(5): e955 - e977. [Abstract] [Full Text] [PDF]

				Part 6: Pediatric Basic and Advanced Life Support Circulation, November 29, 2005; 112(22_suppl): III-73 - III-90. [Full Text] [PDF]

				A Y Patwala and D J Wright Device based treatment of heart failure Postgrad. Med. J., May 1, 2005; 81(955): 286 - 291. [Abstract] [Full Text] [PDF]

				D. G Katritsis and A.J. Camm Nonsustained ventricular tachycardia: where do we stand? Eur. Heart J., July 1, 2004; 25(13): 1093 - 1099. [Abstract] [Full Text] [PDF]

				G. D. Sanders, M. A. Hlatky, N. R. Every, K. M. McDonald, P. A. Heidenreich, L. S. Parsons, and D. K. Owens Potential Cost-Effectiveness of Prophylactic Use of the Implantable Cardioverter Defibrillator or Amiodarone after Myocardial Infarction Ann Intern Med, November 20, 2001; 135(10): 870 - 883. [Abstract] [Full Text] [PDF]

				S. J. Connolly Evidence-Based Analysis of Amiodarone Efficacy and Safety Circulation, November 9, 1999; 100(19): 2025 - 2034. [Full Text] [PDF]

				P. J. Welch, R. L. Page, and M. H. Hamdan Management of ventricular arrhythmias: A trial-based approach J. Am. Coll. Cardiol., September 1, 1999; 34(3): 621 - 630. [Abstract] [Full Text] [PDF]

				P. Kovoor, V. Eipper, K. Byth, M.J. Cooper, J.B. Uther, and D.L. Ross Comparison of sotalol with amiodarone for long-term treatment of spontaneous sustained ventricular tachyarrhythmia based on coronary artery disease Eur. Heart J., March 1, 1999; 20(5): 364 - 374. [Abstract] [PDF]

				M. K. Chung, R. A. Schweikert, B. L. Wilkoff, M. J. Niebauer, S. L. Pinski, R. G. Trohman, G. A. Kidwell, F. J. Jaeger, V. A. Morant, D. P. Miller, et al. Is hospital admission for initiation of antiarrhythmic therapy with sotalol for atrial arrhythmias required?: yield of in-hospital monitoring and prediction of risk for significant arrhythmia complications J. Am. Coll. Cardiol., July 1, 1998; 32(1): 169 - 176. [Abstract] [Full Text] [PDF]

				I. Sim, K. M. McDonald, P. W. Lavori, C. M. Norbutas, and M. A. Hlatky Quantitative Overview of Randomized Trials of Amiodarone to Prevent Sudden Cardiac Death Circulation, November 4, 1997; 96(9): 2823 - 2829. [Abstract] [Full Text]

				J. A. Reiffel Data-driven Decisions: The Importance of Clinical Trials in Arrhythmia Management Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1996; 1(1): 79 - 88. [Abstract] [PDF]

				M. J. Silver, J. Young, E. J. Topol, A. Colli, L. A. Sechi, S. De Carli, E. Bartoli, S. N. Singh, R. D. Fletcher, and S. G. Fisher Amiodarone in Congestive Heart Failure N. Engl. J. Med., December 14, 1995; 333(24): 1639 - 1641. [Full Text]

				M. O. Sweeney, J. N. Ruskin, H. Garan, B. A. McGovern, M. L. Guy, D. F. Torchiana, G. J. Vlahakes, J. B. Newell, M. J. Semigran, and G. W. Dec Influence of the Implantable Cardioverter/Defibrillator on Sudden Death and Total Mortality in Patients Evaluated for Cardiac Transplantation Circulation, December 1, 1995; 92(11): 3273 - 3281. [Abstract] [Full Text]

				N. A. Omoigui, F. I. Marcus, J. W. Mason, E. A. Hahn, V. L. Hartz, and M. A. Hlatky Cost of Initial Therapy in the Electrophysiological Study Versus ECG Monitoring Trial (ESVEM) Circulation, February 15, 1995; 91(4): 1070 - 1076. [Abstract] [Full Text]

				D. M. Roden Risks and Benefits of Antiarrhythmic Therapy N. Engl. J. Med., September 22, 1994; 331(12): 785 - 791. [Full Text]